KALA BIO, Inc. (NASDAQ:KALA) Short Interest Update

KALA BIO, Inc. (NASDAQ:KALA) was the recipient of a significant decrease in short interest in the month of December. As of December 15th, there was short interest totalling 21,500 shares, a decrease of 18.3% from the November 30th total of 26,300 shares. Based on an average trading volume of 26,200 shares, the days-to-cover ratio is presently 0.8 days. Approximately 0.6% of the shares of the company are short sold.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of KALA BIO in a report on Friday, November 15th.

Insider Transactions at KALA BIO

In related news, major shareholder Bros. Advisors Lp Baker acquired 310,559 shares of the stock in a transaction on Monday, December 30th. The shares were acquired at an average price of $6.44 per share, for a total transaction of $1,999,999.96. Following the transaction, the insider now owns 1,083,398 shares in the company, valued at approximately $6,977,083.12. This trade represents a 40.18 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 8.32% of the company’s stock.

Institutional Investors Weigh In On KALA BIO

An institutional investor recently bought a new position in KALA BIO stock. SR One Capital Management LP acquired a new position in shares of KALA BIO, Inc. (NASDAQ:KALA) in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 443,661 shares of the company’s stock, valued at approximately $3,146,000. KALA BIO makes up about 1.0% of SR One Capital Management LP’s portfolio, making the stock its 9th biggest holding. SR One Capital Management LP owned approximately 15.76% of KALA BIO as of its most recent filing with the SEC. Hedge funds and other institutional investors own 24.61% of the company’s stock.

KALA BIO Trading Up 1.0 %

KALA stock traded up $0.07 during trading on Tuesday, reaching $6.94. 30,129 shares of the stock were exchanged, compared to its average volume of 77,429. The company has a current ratio of 2.15, a quick ratio of 2.15 and a debt-to-equity ratio of 3.18. The firm has a market capitalization of $31.99 million, a price-to-earnings ratio of -0.56 and a beta of -2.15. The business has a 50 day moving average price of $6.60 and a 200-day moving average price of $6.24. KALA BIO has a 1 year low of $4.21 and a 1 year high of $9.25.

KALA BIO (NASDAQ:KALA) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.93) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.43) by $0.50. On average, research analysts predict that KALA BIO will post -10.84 earnings per share for the current year.

KALA BIO Company Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.